In February 2004, Pennsylvania based Protez Pharmaceuticals, developer of novel antibiotics for difficult-to-treat infections, acquired the assets of Influx, Influx is a biotechnology company that discovers and develops therapies that, when given in combination with current antimicrobial treatments inhibit resistance mechanisms and effectively treat drug resistant infections. Protox Pharmaceuticals is itself a small firm formed in late 2003 with support from BTG, a global technology commercialization company located in PA.
